Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.

Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM.

J Alzheimers Dis. 2016 Nov 19;55(2):813-822.

PMID:
27792012
2.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN)..

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0.

PMID:
27777020
3.

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.

Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM.

Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104. doi: 10.1016/j.jagp.2016.04.004.

PMID:
27426238
4.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network..

Alzheimers Dement. 2016 Aug 29. pii: S1552-5260(16)30048-6. doi: 10.1016/j.jalz.2016.07.005. [Epub ahead of print]

PMID:
27583651
5.

Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.

Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL.

JAMA Neurol. 2016 Oct 1;73(10):1192-1200. doi: 10.1001/jamaneurol.2016.2642.

PMID:
27548756
6.

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network..

Brain. 2016 Oct;139(Pt 10):2766-2777.

PMID:
27521573
7.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

PMID:
27454922
8.

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.

Ann Neurol. 2016 Sep;80(3):379-87. doi: 10.1002/ana.24719.

PMID:
27398953
9.

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease.

Muenchhoff J, Poljak A, Thalamuthu A, Gupta VB, Chatterjee P, Raftery M, Masters CL, Morris JC, Bateman RJ, Fagan AM, Martins RN, Sachdev PS.

Sci Rep. 2016 Jul 6;6:29078. doi: 10.1038/srep29078.

10.

NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.

Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL.

Neurobiol Aging. 2016 Aug;44:1-8. doi: 10.1016/j.neurobiolaging.2016.03.025.

PMID:
27318129
11.

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL.

Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139.

PMID:
27286736
12.

Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning.

Hassenstab J, Chasse R, Grabow P, Benzinger TL, Fagan AM, Xiong C, Jasielec M, Grant E, Morris JC.

Neurobiol Aging. 2016 Jul;43:23-33. doi: 10.1016/j.neurobiolaging.2016.03.014.

PMID:
27255812
13.

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM.

Sci Transl Med. 2016 May 11;8(338):338ra66. doi: 10.1126/scitranslmed.aaf2362.

PMID:
27169802
14.

Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid.

Ju YE, Finn MB, Sutphen CL, Herries EM, Jerome GM, Ladenson JH, Crimmins DL, Fagan AM, Holtzman DM.

Ann Neurol. 2016 Jul;80(1):154-9. doi: 10.1002/ana.24672.

PMID:
27129429
15.

Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC.

Alzheimer Dis Assoc Disord. 2016 Apr 28. [Epub ahead of print]

PMID:
27128959
16.

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

17.

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2016 May 1;73(5):561-71. doi: 10.1001/jamaneurol.2016.0086.

PMID:
27018940
18.

White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Ryan NS, Förster S, Laske C, Schofield PR, Sperling RA, Salloway S, Correia S, Jack C Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network..

Ann Neurol. 2016 Jun;79(6):929-39. doi: 10.1002/ana.24647.

PMID:
27016429
19.

Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.

Xiong C, Jasielec MS, Weng H, Fagan AM, Benzinger TL, Head D, Hassenstab J, Grant E, Sutphen CL, Buckles V, Moulder KL, Morris JC.

Neurology. 2016 Apr 19;86(16):1499-506. doi: 10.1212/WNL.0000000000002593.

PMID:
27009258
20.

Spatial Navigation in Preclinical Alzheimer's Disease.

Allison SL, Fagan AM, Morris JC, Head D.

J Alzheimers Dis. 2016 Feb 9;52(1):77-90. doi: 10.3233/JAD-150855.

Items per page

Supplemental Content

Loading ...
Support Center